Aravive, Inc. (ARAV)
| Market Cap | 61.87M |
| Revenue (ttm) | 12.14M |
| Net Income (ttm) | -30.24M |
| Shares Out | 20.97M |
| EPS (ttm) | -1.68 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 96,941 |
| Open | 2.85 |
| Previous Close | 2.79 |
| Day's Range | 2.76 - 2.98 |
| 52-Week Range | 2.41 - 9.95 |
| Beta | 3.08 |
| Analysts | Strong Buy |
| Price Target | 22.00 (+645.8%) |
| Earnings Date | Nov 3, 2021 |
About ARAV
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, HER negative breast cancer, uterine, pancreatic cancer, urothelial, and non-small-cell lung cancers. The company also develops AVB-S6, a soluble Fc-fusion protein to blo...
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for Aravive stock is "Strong Buy." The 12-month stock price forecast is 22.00, which is an increase of 645.76% from the latest price.
News
Aravive to Participate in Fireside Chat at Piper Sandler 33rd Annual Virtual Healthcare Conference
HOUSTON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative, targeted therapeutics to treat life-threatening cancers, today annou...
Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with ...
3 of 5 (60%) patients achieved a partial response All 5 patients treated demonstrated tumor decrease from baseline Batiraxcept has been generally well-tolerated with no dose-limiting toxicities Aravive ...
Aravive (ARAV) Reports Q3 Loss, Tops Revenue Estimates
Aravive (ARAV) delivered earnings and revenue surprises of -26.19% and 2.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Aravive Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
HOUSTON, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative, targeted therapeutics to treat life-threatening cancers, today annou...
Aravive to Participate in Fireside Chat at Cantor Fitzgerald Virtual Global Healthcare Conference
HOUSTON, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Ga...
Aravive to Participate in Fireside Chat at H.C. Wainwright 23rd Annual Global Investment Conference
HOUSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Ga...
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenoca...
Trial to Evaluate AVB-500 as a First-Line Treatment in Combination with Gemcitabine and Nab-Paclitaxel
Aravive Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
HOUSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced recent c...
Aravive to Participate in Fireside Chat at 2021 BTIG Biotechnology Conference
HOUSTON, July 27, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Gai...
Aravive Achieves Second Development Milestone from 3D Medicines
Milestone is Based on Approval of 3D Medicines' IND in China to Participate in Aravive's AVB-500 (3D-299) Phase 3 Clinical Trial for Platinum Resistant Ovarian Cancer Milestone is Based on Approval of 3...
Aravive to Participate in Fireside Chat at 2021 William Blair Biotech Focus Conference
HOUSTON, July 07, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Gai...
Aravive (ARAV) Reports Q1 Loss, Lags Revenue Estimates
Aravive (ARAV) delivered earnings and revenue surprises of 2.22% and -54.69%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Re...
Addresses High Unmet Medical Need for Women with Advanced Ovarian Cancer
Aravive to Present Phase 1b Data Evaluating AVB-500 in Platinum Resistant Ovarian Cancer at 2021 Society of Gynecolog...
HOUSTON, March 12, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq:ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that updated data from its Phase 1b tri...
Aravive Announces $21.0 Million Registered Direct Offering with Eshelman Ventures, LLC Priced At-The-Market
HOUSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that it has entered into a securities p...
Aravive to Present at the H.C. Wainwright Virtual BioConnect Conference
HOUSTON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the Company will present at the H.C. Wa...
Aravive Announces Board Member Transition to Advisory Role
HOUSTON, Dec. 31, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that Dr. Ray Tabibiazar will be steppin...
Aravive to Host Virtual Expert Event Focused on Ovarian and Renal Cancer on November 20, 2020
HOUSTON, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the Company will host a virtual Ovarian...
Aravive Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
HOUSTON, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced recent corporate updates and financial ...
Aravive Appoints Michael W. Rogers to Board of Directors
Strengthens Advisory Team with Industry Veteran as Company Advances AVB-500 in Platinum Resistant Ovarian Cancer (PROC) Strengthens Advisory Team with Industry Veteran as Company Advances AVB-500 in Pla...
Aravive Appoints Reshma Rangwala, M.D., Ph.D., as Chief Medical Officer
HOUSTON, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the appointment of industry veteran ...
Aravive to Participate in Upcoming Virtual Investor Conferences in September
HOUSTON, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that the Company will present and co...
Aravive Strengthens Leadership Team with Appointment of Key Industry Veterans
Expands Clinical Development and Oncology Expertise as Company Advances AVB-500 in Platinum Resistant Ovarian Cancer Expands Clinical Development and Oncology Expertise as Company Advances AVB-500 in Pl...
Aravive Reports Second Quarter 2020 Financial Results and Provides Recent Corporate Updates
HOUSTON, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced recent corporate updates and financia...
Aravive to Participate in Upcoming Virtual Investor Conferences in August
HOUSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that the Company will present and con...